NEW YORK (May 5, 2016) – Human Microbiology Institute is delighted to announce that its scientific core played a primary role in the groundbreaking study for the treatment of dementia in end-stage Alzheimer’s disease.
The article that describes this clinical case will be presented in the Journal of Medical Case Reports.
It describes the case of patient with severe dementia secondary to Alzheimer’s disease with extremely low levels of clinical and research settings measuring cognitive impairment, who began treatment with a novel experimental drug candidate. We were the first to successfully removed from the terminal state of Alzheimer’s disease.
“The field of neurodegenerative diseases holds great potential for today’s medicine,” said Dr. V. Tetz, the head of the scientific core of Human Microbiology Institute. “Data for the study being presented in this article include a first-time clinical case of removing patient from advanced, terminal stage of the Alzheimer’s disease, as well as first-time data of the successful repurposing of an old drug for this pathology.”
“We plan to expand our study to other neurodegenerative diseases including Parkinson’s disease and dementia” said George Tetz, head of R&D department for the Human Microbiology Institute
Alzheimer’s disease is the most common cause of dementia, and is characterized by a progressive loss of brain tissue leading to amyloid-b accumulation and severe decline in cognitive function. More than 5 million Americans are living with Alzheimer’s disease. The cause of this pathology is poorly understood, and available treatments are limited in their efficacy, particularly for patients with more severe symptoms.